In recent studies, the reported prevalence of heterozygous familial hypercholesterolemia (FH) has been higher than in previous reports. Although cascade genetic screening is a good option for efficient identification of affected patients, diagnosis using only clinical criteria is more common in real clinical practice. Cardiovascular risk is much higher in FH patients due to longstanding low density lipoprotein cholesterol (LDL-C) burden and is also influenced by other risk factors. Although guidelines emphasize aggressive LDL-C reduction, the majority of patients cannot reach the LDL-C goal by conventional pharmacotherapy. Novel therapeutics such as proprotein convertase subtilisin/kexin type 9 inhibitors have shown strong lipid lowering efficacy and are expected to improve treatment results in FH patients.

Citations

Citations to this article as recorded by  

• Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan® Tablet) in Patients with Concomitant Hypertension and Hyperlipidemia: An Observational Study
  Kwang Je Lee, Jae-Kean Ryu, Yun-Hyeong Cho, Won Yong Shin, Jeong Su Kim, Young Won Yoon, Ji Yong Jang, Won Ho Kim, Jong Wook Beom, Seok-Min Kang
  Drug Design, Development and Therapy.2023; Volume 17: 1047.     CrossRef
• Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
  Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Christopher Wai Kei Lam
  Endocrinology and Metabolism.2021; 36(2): 279.     CrossRef
• Identification and Functional Characterization of a Low-Density Lipoprotein Receptor Gene Pathogenic Variant in Familial Hypercholesterolemia
  Hong-Yan Shu, Wei Zhang, Cong-Cong Zheng, Man-Yun Gao, Yong-Cun Li, Yan-Gang Wang
  Frontiers in Genetics.2021;[Epub]     CrossRef
• Gut Microbiota and Complications of Type-2 Diabetes
  Camelia Oana Iatcu, Aimee Steen, Mihai Covasa
  Nutrients.2021; 14(1): 166.     CrossRef
• LDLR Gene Mutation p.Asp360His and Familial Hypercholesterolemia in a Mexican Community
  Teresita De Jesús Hernández Flores, Juan Ramón González García, Yoaly Josefina Sánchez López, Norma Alejandra Vázquez Cárdenas, Ana Gabriela Colima Fausto, Sergio Yair Rodríguez Preciado, María Teresa Magaña Torres
  Archives of Medical Research.2020; 51(2): 153.     CrossRef
• A Rare Double Heterozygous Mutation in Low-Density Lipoprotein Receptor and Apolipoprotein B-100 Genes in a Severely Affected Familial Hypercholesterolaemia Patient
  Lilla Juhász, István Balogh, László Madar, Beáta Kovács, Mariann Harangi
  Cureus.2020;[Epub]     CrossRef
• Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study
  Kyoung Im Cho, Bo Hyun Kim, Yong Hyun Park, Jeong-Cheon Ahn, Sang Hyun Kim, Wook Jin Chung, Weon Kim, Il Suk Sohn, Jin Ho Shin, Yong Jin Kim, Kiyuk Chang, Cheol Woong Yu, Soe Hee Ahn, Seok Yeon Kim, Jae Kean Ryu, Jong Young Lee, Bum Kee Hong, Taek Jong Ho
  Clinical Therapeutics.2019; 41(8): 1508.     CrossRef
• Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
  Mary P. McGowan, Seyed Hamed Hosseini Dehkordi, Patrick M. Moriarty, P. Barton Duell
  Journal of the American Heart Association.2019;[Epub]     CrossRef
• Autosomal recessive hypercholesterolemia: Case report
  Zaneta Petrulioniene, Urte Gargalskaite, Violeta Mikstiene, Rimvydas Norvilas, Egle Skiauteryte, Algirdas Utkus
  Journal of Clinical Lipidology.2019; 13(6): 887.     CrossRef
• Q192R polymorphism in the PON1 gene and familial hypercholesterolemia in a Saudi population
  Khalid Khalaf Alharbi, May Salem Alnbaheen, Fawiziah Khalaf Alharbi, Rana M. Hasanato, Imran Ali Khan
  Annals of Saudi Medicine.2017; 37(6): 425.     CrossRef